Published in Gene Therapy Weekly, December 13th, 2001
The trial also demonstrated that the VEGF165 gene delivered with Valentis' lipid delivery system was as effective as the VEGF165 gene delivered by an adenoviral vector. Additionally, the safety issues associated with adenoviral vectors were not seen in patients receiving the gene delivered with Valentis' lipid delivery...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly